Pharmacological otoprotection strategies against cisplatin-induced ototoxicity

References

• Weijl N, Hopman G, Wipkink-Bakker A, Lentjes E, Berger H, Cleton FJ, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998; 9: 1331–7
   PubMed Web of Science ®Google Scholar
• Feghali J, Liu W, van de Water T. L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope. 2001; 111: 1147–55
   PubMed Web of Science ®Google Scholar
• Kopke R, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol. 1997; 18: 559–71
   PubMedGoogle Scholar
• Rybak L, Ravi R, Somani S. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995; 26: 293–300
   PubMedGoogle Scholar
• Cardinaal R, De Groot J, Huizing E, Veldman J, Smoorenburg G. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs?. Hear Res. 2000; 144: 147–56
   PubMed Web of Science ®Google Scholar
• Smoorenburg G, De Groot J, Hamers F, Klis S. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann N Y Acad Sci. 1999; 884: 192–210
   PubMed Web of Science ®Google Scholar
• van Ruijven M, De Groot J, Smoorenburg G. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res. 2004; 197: 44–54
   PubMed Web of Science ®Google Scholar
• van Ruijven M, De Groot J, Klis S, Smoorenburg G. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005; 205: 241–8
   PubMed Web of Science ®Google Scholar
• Usami S, Hjelle O, Ottersen O. Differential cellular distribution of glutathione: an endogenous antioxidant in the guinea pig inner ear. Brain Res. 1996; 743: 337–40
   PubMed Web of Science ®Google Scholar
• Sha SH, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res. 2001; 155: 1–8
   PubMed Web of Science ®Google Scholar
• Jones M, Basinger M, Beaty J, Holscher M. The relative nephrotoxicity of cisplatin, cis-Pt (NH3)2(guanosine) 2 2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol. 1991; 29: 29–32
   PubMed Web of Science ®Google Scholar
• Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol. 2003; 51: 36–42
   PubMed Web of Science ®Google Scholar
• Hatzopoulos S, Di Stefano M, Albertin A, Martini A. Evaluation of cisplatin ototoxicity in a rat animal model. Ann N Y Acad Sci. 1999; 884: 211–25
   PubMed Web of Science ®Google Scholar
• Rybak L, Whitworth C. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005; 10: 1313–21
   PubMed Web of Science ®Google Scholar
• Geming L, Wei L, Dorothy F. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. NeuroToxicology. 2006; 27: 22–30
   PubMed Web of Science ®Google Scholar
• Beneditti Panici P, Greggi S, Scambia G, Baiocchi G, Lomonaco M, Conti G, et al. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: four-year survival analysis and neurological follow-up. Int J Gynecol Cancer. 1993; 3: 44–53
   PubMed Web of Science ®Google Scholar
• Clerici W, Hensley K, DiMartino D, Butterfield D. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res. 1996; 98: 116–24
   PubMed Web of Science ®Google Scholar
• Gilbert D. Fifty years of radical ideas. Ann N Y Acad Sci. 2000; 899: 1–14
   PubMed Web of Science ®Google Scholar
• Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. Br J Nutr. 2001; 85(Suppl 2)S67–74
   PubMed Web of Science ®Google Scholar
• Rybak L, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol. 2000; 21: 513–20
   PubMedGoogle Scholar
• Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Rad Biol & Med. 2002; 33: 182–91
   PubMed Web of Science ®Google Scholar
• Neuwelt E, Pagel M, Hasler B, Deloughery T, Muldoon L. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res. 2001; 61: 7868–74
   PubMed Web of Science ®Google Scholar
• Lorito G, Giordano P, Prosser S, Martini A, Hatzopoulos S. Noise induced hearing loss: a study on pharmacological protection in the Sprague-Dawley rat with N-acetylcysteine. Acta Otorhinolaryncol Ital. 2006; 26: 133–9
   PubMedGoogle Scholar
• Dickey D, Muldoon L, Kraemer D, Neuwelt E. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res. 2004; 193: 25–30
   PubMed Web of Science ®Google Scholar
• Campbell K, Meech R, Rybak L, Hughes L. D-methionine protects against cisplatin damage to the stria vascularis. Hear Res. 1999; 138: 13–28
   PubMed Web of Science ®Google Scholar
• Campbell K, Meech R, Rybak L, Hughes L. The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. J Am Acad Audiol. 2003; 14: 144–56
   PubMedGoogle Scholar
• Giordano P, Lorito G, Ciorba A, Martini A, Hatzopoulos S. Protection against cisplatin ototoxicity in a Sprague-Dawley rat animal model. Acta Otorhinolarygol Ital. 2006; 26: 198–207
   PubMedGoogle Scholar
• Teranishi M, Nakashima T, Wakabayashi T. Effects of alphatocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res. 2001; 151: 61–70
   PubMed Web of Science ®Google Scholar
• Kalkanis J, Whitworth C, Rybak L. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004; 114: 538–42
   PubMed Web of Science ®Google Scholar
• Hattori R, Inoue R, Sase K, Eizawa H, Kosuga K, Aoyama T, et al. Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur J Pharmacol. 1994; 267: 1–2
   PubMed Web of Science ®Google Scholar
• Hoshida S, Aoki K, Nishida M, Yamashita N, Igarashi J, Hori M, et al. Effects of preconditioning with ebselen on glutathione metabolism and stress protein expression. J Pharmacol Exp Ther. 1997; 281: 1471–5
   PubMed Web of Science ®Google Scholar
• Lass A, Witting P, Stocker R, Esterbauer H. Inhibition of copper and peroxyl radical-induced LDL lipid oxidation by ebselen: antioxidant actions in addition to hydroperoxide-reducing activity. Biochim Biophys. 1996; 1303: 111–8
   PubMed Web of Science ®Google Scholar
• Muller A, Cardenas E, Graf P, Sies H. A novel biologically active seleno-organic compound-I. Biochem. Pharmacol. 1984; 33: 3225–9
   Google Scholar
• Narayanaswami V, Sies H. Oxidative damage to mitochondria and protection by ebselen and other antioxidants. Biochem Pharmacol. 1990; 40: 1623–9
   PubMed Web of Science ®Google Scholar
• Schewe T. Molecular actions of ebselen – an anti-inflammatory antioxidant. Gen Pharmacol. 1995; 26: 1153–69
   PubMedGoogle Scholar
• Lynch E, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005; 201: 81–9
   PubMed Web of Science ®Google Scholar
• Schweitzer V. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 1993; 103: 1–52
   PubMed Web of Science ®Google Scholar
• Treskes M, Nijtmans L, Fichtinger-Schepman A, van der Vijgh W. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro compared to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol. 1992; 43: 1013–9
   PubMed Web of Science ®Google Scholar
• Lempers E, Reedijk J. Reversibility of cisplatinmethionine in proteins by diethyldithiocarbamate or thiourea: a study with model adducts. Inorgan. Chem. 1990; 29: 217–22
   Web of Science ®Google Scholar
• Ekborn A, Laurell G, Johnstrom P, Wallin I, Eksborg S, Ehrsson H. D-methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear Res. 2002; 165: 53–61
   PubMed Web of Science ®Google Scholar
• Heudi O, Cailleaux A, Allain P. Kinetic studies of the reactivity between cisplatin and its monoaquo species with L-methionine. J Inorg Biochem. 1998; 71: 61–9
   Web of Science ®Google Scholar
• Daley-Yates P, McBrien D. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol. 1984; 33: 3063–70
   PubMed Web of Science ®Google Scholar
• Leppala J, Virtamo J, Fogelholm R. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000; 20: 230–5
   PubMed Web of Science ®Google Scholar
• Light J, Silverstein H. Transtympanic perfusion: indications and limitations. Curr Opin Otolaryngol Head Neck Surg. 2004; 12: 378–83
   PubMedGoogle Scholar
• Halliwell B, Gutteridge J. Free Radicals in Biology and Medicine. Oxford University Press, Oxford 1993; 188–276
   Google Scholar
• Fetoni A, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol. 2004; 124: 421–6
   PubMed Web of Science ®Google Scholar